Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Operational Update

18 May 2017 07:00

RNS Number : 4791F
Itaconix PLC
18 May 2017
 

18 May 2017

Itaconix plc ("Itaconix" or the "Group")

Operational Update

Itaconix, a leading designer and manufacturer of specialty polymers, announces that following the acquisition and integration of Itaconix Corporation in the USA, it is implementing operational changes to the Group. Resources will be more focused on successfully executing the Group's strategy to launch and grow the sales of its products, primarily in the global personal care and homecare markets, including the development of application data that provides clear evidence of the material benefits of using Itaconix's products and how they can be best formulated into end consumer products.

Given the Group's established product portfolio and evolving sales and marketing focus, its need for new product development is becoming more defined and targeted to customer requirements. Accordingly, it is now appropriate to resize the R&D team, which will result in operational efficiencies. Whilst the full financial effect of these changes will not be achieved immediately, with the net cash impact being broadly neutral in 2017, the positive net cash impact is expected to be approximately £1m per annum from 2018.

"The re-balancing of our business is an important step in establishing and growing our product sales and increasing operational efficiencies." said Dr. Kevin Matthews, CEO of Itaconix. "In the short to medium term we are highly focused on our sales and marketing efforts to drive our existing product portfolio into market, and the new structure does mean that some of our team are leaving us. In particular, I would like to thank Dr David Pears our CTO since January 2008 for his unrelenting efforts; David will be retiring from the business at the end of May 2018 after more than 10 years of service. The board firmly believes that an increased effort and focus on product commercialisation is the right direction of travel for the business and that the reduction in our cost base will help accelerate Itaconix's path to profitability.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Ends

For further information please contact:

Itaconix

+44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

N+1 Singer

+44 (0) 207 496 3000

Richard Lindley / Liz Yong (Corporate Finance)

Nick Owen (Corporate Broking)

Hudson Sandler

Charlie Jack / Emily Dillon +44 (0) 207 796 4133

About Itaconix

Itaconix is developing proprietary ingredients that meet the performance and price needs of its customers and offers them improved safety and sustainability, thereby helping to deliver on the global sustainability agenda, with particular emphasis on the Personal Care and Homecare markets.

 

 

www.itaconix.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTARMRTMBIBBMR
Date   Source Headline
9th Feb 20227:00 amRNSFirst Trial for Sustainable Superabsorbent
3rd Feb 20227:00 amRNSNew Patent Filed for Plant-Based Ingredient
26th Jan 20222:05 pmRNSSecond Price Monitoring Extn
26th Jan 20222:00 pmRNSPrice Monitoring Extension
26th Jan 20227:00 amRNSTrading Update
10th Jan 20227:15 amRNSInitiation of Research
22nd Dec 20217:00 amRNSFirst Order for New Use in Sustainable Fashion
21st Dec 20219:05 amRNSSecond Price Monitoring Extn
21st Dec 20219:00 amRNSPrice Monitoring Extension
21st Dec 20217:00 amRNSStatement re Production Resumption
9th Dec 202111:06 amRNSSecond Price Monitoring Extn
9th Dec 202111:00 amRNSPrice Monitoring Extension
4th Nov 20217:00 amRNSProduction Interruption from Storm Damage
1st Oct 20214:41 pmRNSSecond Price Monitoring Extn
1st Oct 20214:36 pmRNSPrice Monitoring Extension
1st Oct 20212:05 pmRNSSecond Price Monitoring Extn
1st Oct 20212:00 pmRNSPrice Monitoring Extension
28th Sep 20217:00 amRNSInterim Results
23rd Sep 20214:41 pmRNSSecond Price Monitoring Extn
23rd Sep 20214:36 pmRNSPrice Monitoring Extension
23rd Sep 20217:00 amRNSNotice of Interim Results & Investor Presentation
16th Sep 202112:13 pmRNSSecond Price Monitoring Extn
16th Sep 202112:12 pmRNSSecond Price Monitoring Extn
16th Sep 202112:12 pmRNSPrice Monitoring Extension
14th Sep 20214:41 pmRNSSecond Price Monitoring Extn
14th Sep 20214:36 pmRNSPrice Monitoring Extension
14th Sep 202111:06 amRNSSecond Price Monitoring Extn
14th Sep 202111:01 amRNSPrice Monitoring Extension
9th Sep 20217:00 amRNSFirst EU Order for Latest Detergent Ingredient
26th Aug 20217:00 amRNSChange of Adviser
27th Jul 20219:05 amRNSSecond Price Monitoring Extn
27th Jul 20219:00 amRNSPrice Monitoring Extension
27th Jul 20217:00 amRNSTrading Statement
19th Jul 202111:05 amRNSSecond Price Monitoring Extn
19th Jul 202111:00 amRNSPrice Monitoring Extension
19th Jul 20217:00 amRNSRemoval of US Securities Law Restrictions
24th Jun 20213:18 pmRNSResult of Annual General Meeting
18th Jun 20217:00 amRNSChanges to AGM Arrangements, Investor Presentation
9th Jun 20219:00 amRNSPrice Monitoring Extension
9th Jun 20217:00 amRNSCompleted New Funding with Institutional Investors
8th Jun 20212:05 pmRNSSecond Price Monitoring Extn
8th Jun 20212:00 pmRNSPrice Monitoring Extension
8th Jun 202111:05 amRNSSecond Price Monitoring Extn
8th Jun 202111:00 amRNSPrice Monitoring Extension
8th Jun 20217:00 amRNSTrading Update
27th May 20217:00 amRNSNotice of AGM
20th May 20214:41 pmRNSSecond Price Monitoring Extn
20th May 20214:35 pmRNSPrice Monitoring Extension
20th May 20217:00 amRNSItaconix receives the LSE's Green Economy Mark
9th Apr 20211:07 pmRNSIssue of Shares, Director/PDMR Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.